A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

<h4>Background</h4>We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk.&l...

Full description

Saved in:
Bibliographic Details
Main Authors: Christine Schmucker, Christoph Ehlken, Hansjuergen T Agostini, Gerd Antes, Gerta Ruecker, Monika Lelgemann, Yoon K Loke
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2012
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/c5e008556eeb4130b932c3f8d52cf1c0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items